Empaglifozin and the reduction of risk of death in a high cardiovascular risk population
Ítalo Cordeiro Moreira, Gabriel Pereira Bernardo, D'ávila Suyane Belém de Lima, Cecília Brenda Rocha Carneiro, Débora Laésia Saraiva Ribeiro, Mariana Carleial Feijó de Sá, Maria Jaionara de Macedo, Priscila Passos Campelo Moreira, Vanessa Lacerda Araújo, José Nunes de Alencar, Herbert Lima Mendes, Sérgio de Araújo, Hermes Melo Teixeira Batista · International Archives of Medicine · 2016
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
International Archives of Medicine · International Medical Society · article · 2016
Abstract
Diabetes Mellitus (DM) is a chronic cardio-metabolic disease and plays an important role on cardiovascular outcomes, most importantly when associated with an already established heart disease. Its effects in the body involve both metabolic and structural changes. To avoid such complications, in addition to the strategies already used and known, rises the Empaglifozin, a sodium glucose co-transporter inhibitor 2 (SGLT2). Its benefits and efficacy have been tried and tested in large-scale trials, with multidimensional cardiovascular effects that go beyond the adequate glycemic control.
The EMPA-REG Outcome materialize such benefits, especially for people at high cardiovascular risk, when significantly reduced cardiovascular death and death from any cause in this population.
Open the resolved locator · 10.3823/2000
Metadata licence: OpenAlex metadata (CC0)